Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

JW Therapeutics Approved to Launch CAR-T for Second Lymphoma Indication

publication date: Oct 10, 2022

Shanghai JW Therapeutics reported that its CAR-T immunotherapy, relmacabtagene, was approved in China as a second-line treatment for follicular lymphoma. The NMPA approved the anti-CD19 cell immunotherapy to treat adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment. One year ago, the candidate was approved in China as a third-line therapy for large B-cell lymphoma. JW is a joint venture formed by Seattle's Juno Therapeutics, a cell therapy biotech, and WuXi AppTec, a China CRO/CMO. More details....

Stock Symbol: (HK: 2126)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here